[HTML][HTML] Continuing bisphosphonate treatment for osteoporosis—for whom and for how long?
New England Journal of Medicine, 2012•Mass Medical Soc
Continuing Bisphosphonate Treatment for Osteoporosis — For Whom and for How Long? |
NEJM Skip to main content NEJM Group Follow Us Facebook Twitter Instagram YouTube
LinkedIn Prepare to become a physician, build your knowledge, lead a health care organization,
and advance your career with NEJM Group information and services. NEJM Evidence NEW!
A digital journal for innovative original research and fresh, bold ideas in clinical trial design
and clinical decision-making. NEJM Catalyst NEW! Peer-reviewed journal featuring in-depth …
NEJM Skip to main content NEJM Group Follow Us Facebook Twitter Instagram YouTube
LinkedIn Prepare to become a physician, build your knowledge, lead a health care organization,
and advance your career with NEJM Group information and services. NEJM Evidence NEW!
A digital journal for innovative original research and fresh, bold ideas in clinical trial design
and clinical decision-making. NEJM Catalyst NEW! Peer-reviewed journal featuring in-depth …
There is controversy over the ideal duration of bisphosphonate therapy for osteoporosis, given reports of atypical subtrochanteric fractures and osteonecrosis of the jaw. But some subgroups of patients may benefit from continuing therapy beyond 3 to 5 years.
The New England Journal Of Medicine